Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 1431

Sort by

Sort Order Select

Journal Articles

Desensitization to calaspargase pegol appears to be less successful than pegaspargase

Milre Matherne, John C. Panetta, Jaclyn Hopp, Hiroto Inaba, Ching-Hon Pui, Seth E. Karol, Hope D. Swanson

Blood Adv (2025) 9 (7): 1492–1496.

https://doi.org/10.1182/bloodadvances.2024015455

Published: 2025

Journal Articles

Phase 2 trial of ibrutinib and nivolumab in patients with relapsed CNS lymphomas

Blood Adv (2025) 9 (7): 1485–1491.

https://doi.org/10.1182/bloodadvances.2024014635

Published: 2025

Journal Articles

Changes in gut microbiota predict neutropenia after induction treatment in childhood acute lymphoblastic leukemia

Maria Ebbesen Sørum, Ulrika Boulund, Silvia De Pietri, Sarah Weischendorff, Christian Enevold, Mathias Rathe, Bodil Als-Nielsen, Henrik Hasle, Sünje Pamp, Jakob Stokholm, Klaus Müller

Blood Adv (2025) 9 (7): 1508–1521.

https://doi.org/10.1182/bloodadvances.2024013986

Published: 2025

Includes: Supplemental data

Journal Articles

Outcomes of older adults and frail patients receiving idecabtagene vicleucel: a CIBMTR study

Blood Adv (2025) 9 (7): 1587–1592.

https://doi.org/10.1182/bloodadvances.2024014970

Published: 2025

Includes: Supplemental data

Journal Articles

Differential antibody response to EBV proteome following EBVST immunotherapy in EBV-associated lymphomas

Yomani D. Sarathkumara, Nathan W. Van Bibber, Zhiwei Liu, Helen E. Heslop, Rayne H. Rouce, Anna E. Coghill, Cliona M. Rooney, Carla Proietti, Denise L. Doolan

Blood Adv (2025) 9 (7): 1658–1669.

https://doi.org/10.1182/bloodadvances.2024014937

Published: 2025

Includes: Supplemental data

Journal Articles

Allogeneic off-the-shelf CAR T-cell therapy for relapsed or refractory B-cell malignancies

Blood Adv (2025) 9 (7): 1644–1657.

https://doi.org/10.1182/bloodadvances.2024015157

Published: 2025

Includes: Supplemental data

Journal Articles

Predicting risk in Hodgkin lymphoma for research and clinical practice

Ruohui Chen, Leo I. Gordon

Blood Adv (2025) 9 (6): 1387–1389.

https://doi.org/10.1182/bloodadvances.2024015742

Published: 2025

Journal Articles

Socioeconomic, racial-ethnic, household, and infrastructural disparities of hematologic cancer outcomes in the United States

David J. Fei-Zhang, Erik Wu, Alexander V. Stanisic, Lifang Hou, Leonidas C. Platanias, Stephen M. Ansell, Marquita W. Lewis-Thames, Sherif M. Badawy, Jonas Paludo

Blood Adv (2025) 9 (6): 1463–1471.

https://doi.org/10.1182/bloodadvances.2024013956

Published: 2025

Includes: Supplemental data

Journal Articles

Clonal relatedness as a prognostic marker in Richter transformation of chronic lymphocytic leukemia: a systematic review

Aisling Barrett, Callum Harris, Toby A. Eyre

Blood Adv bloodadvances.2024015594.

https://doi.org/10.1182/bloodadvances.2024015594

Published: 2025

Journal Articles

Hematopoietic Progenitor Kinase-1 (HPK-1) Inhibition Improves the In Vitro Efficacy of Bispecific Antibodies in CLL

Yamit Shorer Arbel, Liron Yitzhak, Ben-Zion Katz, Yair Herishanu

Blood Adv bloodadvances.2024015242.

https://doi.org/10.1182/bloodadvances.2024015242

Published: 2025

Includes: Multimedia, Supplemental data

Journal Articles

Peripheral T-cell lymphoma-NOS in children and adolescents: a review from the Children’s Oncology Group NHL Committee

Kaitlin J. Devine, Lindsay Schwartz, Nader Kim El-Mallawany

Blood Adv (2025) 9 (6): 1420–1431.

https://doi.org/10.1182/bloodadvances.2024013689

Published: 2025

Journal Articles

Nivolumab and rituximab in treatment-naïve follicular lymphoma: the phase 2 1st FLOR study

Allison Barraclough, Sze Ting Lee, Melinda Burgess, Leonid Churilov, Geoff Chong, Denise Lee, Michael Gilbertson, Tineke Fancourt, Kate Manos, David S. Ritchie, Rachel M. Koldej, Andrew M. Scott, Colm Keane, Eliza A. Hawkes

Blood Adv (2025) 9 (6): 1432–1441.

https://doi.org/10.1182/bloodadvances.2024015487

Published: 2025

Includes: Supplemental data

Journal Articles

Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US experts

Nicholas J. Short, Ibrahim Aldoss, Daniel J. DeAngelo, Marina Konopleva, Jessica Leonard, Aaron C. Logan, Jae Park, Bijal Shah, Wendy Stock, Elias Jabbour

Blood Adv (2025) 9 (6): 1442–1451.

https://doi.org/10.1182/bloodadvances.2024015441

Published: 2025

Journal Articles

Analysis of peripheral neuropathy in the POLARIX study using clinician- and patient-reported outcomes

Marek Trněný, Laura Maria Fogliato, Faithlore Gardner, Ian W. Flinn, Jean-François Larouche, Corinne Haioun, Miguel Angel Canales, Hideki Goto, Roman Hajek, Gilles A. Salles, Avrita Singh, Mark Yan, Rucha Kothari, Gabriel Man, Deniz Sahin, Jamie Hirata, Calvin Lee, MD, Hervé Tilly, Christopher R. Flowers

Blood Adv bloodadvances.2024014695.

https://doi.org/10.1182/bloodadvances.2024014695

Published: 2025

Journal Articles

Subgroup analysis of elderly patients (≥60 years) with diffuse large B-cell lymphoma in the phase 3 POLARIX study

Bei Hu, Patrick M. Reagan, Laurie H. Sehn, Jeff P. Sharman, Mark Hertzberg, Huilai Zhang, Austin I. Kim, Charles Herbaux, Lysiane Molina, Dai Maruyama, Frank Stenner, Saibah Chohan, Rucha Kothari, Connie Lee Batlevi, Jamie Hirata, Deniz Sahin, Calvin Lee, MD, Matthew Sugidono, Hervé Tilly

Blood Adv bloodadvances.2024014707.

https://doi.org/10.1182/bloodadvances.2024014707

Published: 2025

Includes: Supplemental data

Journal Articles

Pediatric relapsed/refractory ALK-positive anaplastic large cell lymphoma treatment and outcomes in the targeted-drug era

Blood Adv (2025) 9 (6): 1356–1365.

https://doi.org/10.1182/bloodadvances.2024014745

Published: 2025

Includes: Supplemental data

Journal Articles

The A-HIPI prediction model in advanced-stage Hodgkin lymphoma: identification of risk groups and creation of an online tool

Matthew J. Maurer, Susan K. Parsons, Jenica N. Upshaw, Angie Mae Rodday, Raphael Mwangi, Sára Rossetti, Jonathan W. Friedberg, Andrea Gallamini, Massimo Federico, Eliza Hawkes, David Hodgson, Peter Johnson, Brian K. Link, Eric Mou, Kerry J. Savage, Pier Luigi Zinzani, Andrew M. Evens

Blood Adv (2025) 9 (6): 1366–1369.

https://doi.org/10.1182/bloodadvances.2024014689

Published: 2025

Journal Articles

Subclonal TP53 and KRAS variants combined with poor treatment response identify ultrahigh-risk pediatric patients with T-ALL

Tamara Kempter, Paulina Richter-Pechańska, Katarzyna Michel, Tobias Rausch, Büşra Erarslan-Uysal, Cornelia Eckert, Martin Zimmermann, Martin Stanulla, Martin Schrappe, Gunnar Cario, Stefan Köhrer, Andishe Attarbaschi, Jan O. Korbel, Joachim B. Kunz, Andreas E. Kulozik

Blood Adv (2025) 9 (6): 1267–1279.

https://doi.org/10.1182/bloodadvances.2024014209

Published: 2025

Includes: Supplemental data

Journal Articles

CAR T-cell reality for R/R LBCL: challenges and challengers

Paolo F. Caimi, Craig S. Sauter

Blood Adv (2025) 9 (5): 1230–1231.

https://doi.org/10.1182/bloodadvances.2024015525

Published: 2025

Journal Articles

Consensus in CLL: global needs matter

Mazyar Shadman, Bita Fakhri, Nitin Jain

Blood Adv (2025) 9 (5): 1210–1212.

https://doi.org/10.1182/bloodadvances.2024015355

Published: 2025

NARROW

Desensitization to calaspargase pegol appears to be less successful than pegaspargase

Phase 2 trial of ibrutinib and nivolumab in patients with relapsed CNS lymphomas

Changes in gut microbiota predict neutropenia after induction treatment in childhood acute lymphoblastic leukemia

Outcomes of older adults and frail patients receiving idecabtagene vicleucel: a CIBMTR study

Differential antibody response to EBV proteome following EBVST immunotherapy in EBV-associated lymphomas

Allogeneic off-the-shelf CAR T-cell therapy for relapsed or refractory B-cell malignancies

Predicting risk in Hodgkin lymphoma for research and clinical practice

Socioeconomic, racial-ethnic, household, and infrastructural disparities of hematologic cancer outcomes in the United States

Clonal relatedness as a prognostic marker in Richter transformation of chronic lymphocytic leukemia: a systematic review

Hematopoietic Progenitor Kinase-1 (HPK-1) Inhibition Improves the In Vitro Efficacy of Bispecific Antibodies in CLL

Peripheral T-cell lymphoma-NOS in children and adolescents: a review from the Children’s Oncology Group NHL Committee

Nivolumab and rituximab in treatment-naïve follicular lymphoma: the phase 2 1st FLOR study

Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US experts

Analysis of peripheral neuropathy in the POLARIX study using clinician- and patient-reported outcomes

Subgroup analysis of elderly patients (≥60 years) with diffuse large B-cell lymphoma in the phase 3 POLARIX study

Pediatric relapsed/refractory ALK-positive anaplastic large cell lymphoma treatment and outcomes in the targeted-drug era

The A-HIPI prediction model in advanced-stage Hodgkin lymphoma: identification of risk groups and creation of an online tool

Subclonal TP53 and KRAS variants combined with poor treatment response identify ultrahigh-risk pediatric patients with T-ALL

CAR T-cell reality for R/R LBCL: challenges and challengers

Consensus in CLL: global needs matter

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only